This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
Responding to unmet needs for metastatic castration-resistant prostate cancer

Podcast series: What’s new in mCRPC?

Read time: 30 mins
Last updated:16th Jan 2024
Published:8th Dec 2023

 

It's true actually that the perception from patients of chemotherapy is not necessarily good, and that's often a difficult conversation.
Professor Karim Fizazi

Professor Karim Fizazi asks Dr Elena Castro about treatment developments, including patients’ perceptions of these, and considerations to make in practice. Log in to listen to the full podcast series.

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

One of the greatest limitations to guidelines is access. I think this is going to be a very pressing issue, as prostate cancer enters precision oncology more and more, that we need to have broad access to both kind of elements: diagnosis and therapies.
Dr Elena Castro

Log in to listen to Professor Karim Fizazi and Dr Elena Castro discuss the available mCRPC guidelines and adapting to clinical reality.

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Not everyone has access to [next-generation sequencing] testing, but I really think it is necessary and very helpful for treatment decisions.
Professor Silke Gillessen

Listen to Professors Karim Fizazi and Silke Gillessen discuss available treatments for mCRPC.

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

[mCRPC] remains the lethal phenotype of the disease.
Professor Karim Fizazi

Listen to Professors Karim Fizazi and Silke Gillessen discuss the latest therapies and potential treatment targets for mCRPC.

Expert-led assessment of relevant clinical guidance

Free scientific information and eLearning for healthcare professionals only

Including CME accreditation, podcasts, webinars and over 50 Learning Zones

Medthority is ad free, so you can learn without distraction

Welcome: